“Compelling Opportunity” | E&P Research Report
Good morning ,On behalf of the Botanix (ASX:BOT) Board of Directors, I am delighted to advise that leading biotech analyst David Nayagam from E&P has published new research on Botanix, which highlights the “compelling opportunity” that the Company presents and initiates coverage with a speculative buy recommendation and price target of $0.55.
The increased interest that we are generating comes at a critical time for Botanix, as we await the commencement of labelling discussions with the FDA – which is the final regulatory hurdle for Sofdra™ – before expected approval in late June 2024.
We are confident that you will find Mr. Nayagam’s in-depth analysis to be informative.
With thanks,
Vince Ippolito
Botanix Executive Chairman
BOT - Post Approval Takeover Predictions, page-32
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
-0.005(1.33%) |
Mkt cap ! $669.7M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 39.0¢ | 37.0¢ | $1.603M | 4.223M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 378157 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 98000 | 5 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |